Rubric Capital Management (New York)’s Nautilus Biotechnolgy NAUT Stock Holding History

Rubric Capital Management (New York)’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-747,607	Closed	-$1.35M	–	86
2022 Q4	$1.35M	Hold	747,607	–	–	0.06%	87
2022 Q3	$1.58M	Hold	747,607	–	–	0.08%	81
2022 Q2	$2.01M	Hold	747,607	–	–	0.11%	79
2022 Q1	$3.24M	Hold	747,607	–	–	0.12%	65
2021 Q4	$3.87M	Hold	747,607	–	–	0.18%	56
2021 Q3	$4.59M	Buy	747,607 +386,463	+107%	+$3.08M	0.13%	51
2021 Q2	$3.65M	Buy	+361,144	New	+$3.91M	0.23%	51

Other funds holding NAUT

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Rubric Capital Management (New York)'s NAUT Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of Nautilus Biotechnolgy (NAUT) in Q1 2023, closing a stake of 747,607 shares — an estimated $1.35M sold.

Rubric Capital Management (New York) first reported a position in NAUT in Q2 2021 and held it in 7 quarters. The position peaked at $4.59M in Q3 2021. 73 funds tracked by Wall St. Rank hold NAUT as of Q1 2023.

Rubric Capital Management (New York) reported no remaining Nautilus Biotechnolgy position as of Q1 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 747,607 Nautilus Biotechnolgy shares in Q1 2023, an estimated $1.35M.
Rubric Capital Management (New York) first reported a position in Nautilus Biotechnolgy in Q2 2021 and held it in 7 quarters.
Rubric Capital Management (New York)'s Nautilus Biotechnolgy position peaked at $4.59M in Q3 2021.
73 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.